GLP-1 Market
LLY $1351.12 ▼ -2.3% NVO $38.87 ▼ -1.4% PFE $27.54 ▼ -1.9% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $58.99 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Human Pancreatic Islets

Company
Ohio State University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 20, 2026

Trial details
  • Completed NCT NCT00501709

    Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

    Not yet reported, Not yet reported University of California, San Francisco 10 participants Est. completion 2016-12 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • No Longer Available NCT NCT01049633

    B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

    National Institute of Allergy and Infectious Diseases (NIAID) 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01571817

    Pancreatic Islet Transplantation Into the Gastric Submucosa

    Not yet reported Andrew Posselt 1 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Suspended NCT NCT01705899

    Islet Allotransplantation in Type 1 Diabetes

    Not yet reported Ohio State University 20 participants Est. completion 2033-10 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.